NASDAQ:DBTX - Decibel Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.75
  • Forecasted Upside: 277.29 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$7.09
▼ -0.04 (-0.56%)

This chart shows the closing price for DBTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Decibel Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DBTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DBTX

Analyst Price Target is $26.75
▲ +277.29% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Decibel Therapeutics in the last 3 months. The average price target is $26.75, with a high forecast of $30.00 and a low forecast of $18.00. The average price target represents a 277.29% upside from the last price of $7.09.

This chart shows the closing price for DBTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Decibel Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/31/2021SVB LeerinkReiterated RatingBuyHigh
5/14/2021SVB LeerinkLower Price TargetOutperform$26.00 ➝ $18.00High
3/9/2021CitigroupInitiated CoverageBuy$29.00High
3/9/2021SVB LeerinkInitiated CoverageOutperform$26.00High
3/9/2021BMO Capital MarketsInitiated CoverageOutperform$30.00High
3/9/2021BarclaysInitiated CoverageOverweight$30.00High
(Data available from 7/25/2016 forward)
Decibel Therapeutics logo
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $7.09
Low: $6.95
High: $7.25

50 Day Range

MA: $8.08
Low: $6.53
High: $9.09

52 Week Range

Now: $7.09
Low: $6.18
High: $24.39

Volume

34,147 shs

Average Volume

179,283 shs

Market Capitalization

$176.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Decibel Therapeutics?

The following equities research analysts have issued reports on Decibel Therapeutics in the last twelve months: Barclays PLC, BMO Capital Markets, Citigroup Inc., SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for DBTX.

What is the current price target for Decibel Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Decibel Therapeutics in the last year. Their average twelve-month price target is $26.75, suggesting a possible upside of 277.3%. Barclays PLC has the highest price target set, predicting DBTX will reach $30.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $18.00 for Decibel Therapeutics in the next year.
View the latest price targets for DBTX.

What is the current consensus analyst rating for Decibel Therapeutics?

Decibel Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DBTX will outperform the market and that investors should add to their positions of Decibel Therapeutics.
View the latest ratings for DBTX.

What other companies compete with Decibel Therapeutics?

How do I contact Decibel Therapeutics' investor relations team?

Decibel Therapeutics' physical mailing address is 1325 Boylston Street Suite 500, Boston MA, 02215. The company's listed phone number is 617 370 8701 and its investor relations email address is [email protected] The official website for Decibel Therapeutics is decibeltx.com.